Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients with New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
March 1, 2016
End Date
August 22, 2018
Administered By
Duke Cancer Institute
Awarded By
Genentech, Inc.
Start Date
March 1, 2016
End Date
August 22, 2018